Why the study?
Hypertensive disorders of pregnancy are common and increase maternal and fetal risks, but uncertainty remains regarding which antihypertensive agents are superior.
What are the safe and effective pharmacotherapeutic options for the treatment of hypertension in pregnancy?
What are the safe and effective pharmacotherapeutic options for the treatment of hypertension in pregnancy?
This review highlights that while several antihypertensives are safe and effective for pregnancy hypertension, the lack of clear superiority among them necessitates personalized treatment choices.
Review of antihypertensives in pregnancy leaves open optimal agent selection; hypothesis-generating pending randomized trials.
INTRODUCTION: Hypertensive disorders of pregnancy affect approximately one in 10 pregnancies and are associated with increased risk of adverse fetal, neonatal and maternal outcomes. There is strong evidence that effective treatment of hypertension (blood pressure ≥ 140/90 mmHg), and enhanced monitoring throughout pregnancy reduces these risks. AREAS COVERED: This article provides a contemporaneous review of treatment of hypertension in pregnancy with antihypertensive agents. We completed a systematic search and review of all meta-analyses and systematic reviews of studies comparing antihypertensives for treatment of pregnancy hypertension in the last five years. We provide a clinically focused summary of when to treat hypertension in pregnancy and which antihypertensive agents can be offered. Special scenarios reviewed include treatment-resistant hypertension and pre-pregnancy antihypertensive optimization. EXPERT OPINION: Several antihypertensives are considered safe and are known to be effective for treatment of hypertension in pregnancy. Given the current uncertainty as to which antihypertensive(s) are superior for treatment of hypertension in pregnancy, women should be counselled and offered a range of antihypertensive options in keeping with evidence on clinical effectiveness, local context and availability of antihypertensive(s), potential side effect profile, and women's preference. Further research is required to help guide clinical decision making, and move toward personalized treatment.
No takes yet. Share an insight, caveat, or question.
Conti‐Ramsden et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: